Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Habib Hamidi

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Cancer Research|November 5, 2002
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumorsJerry Jaboin, Jason Wild, Habib Hamidi, et al.
G3 (Bethesda, Md.)|October 13, 2016
Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three SubtypesGregory P Way, James Rudd, Chen Wang, et al.
The Journal of Clinical Investigation|May 15, 2026
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clustersGaelle Haddad, Junyu Guo, Yin Xi, et al.
Frontiers in Immunology|August 10, 2023
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MMSandy Wong, Habib Hamidi, Luciano J Costa, et al.
Genome Medicine|July 15, 2025
Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroupsEnze Liu, Oumaima Jaouadi, Riya Sharma, et al.
The Prostate|April 18, 2022
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimensKobe C Yuen, Ben Tran, Angelyn Anton, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2022
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple MyelomaFredrik Schjesvold, Bruno Paiva, Vincent Ribrag, et al.
Molecular Oncology|January 24, 2025
Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunctionConnor S Murphy, Heather Fairfield, Victoria E DeMambro, et al.
Leukemia & Lymphoma|January 20, 2022
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemiaPanayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, et al.
Molecular Cancer Therapeutics|March 16, 2013
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growthEdward B Garon, Richard S Finn, Habib Hamidi, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Cancer Research|November 5, 2002
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumorsJerry Jaboin, Jason Wild, Habib Hamidi, et al.
G3 (Bethesda, Md.)|October 13, 2016
Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three SubtypesGregory P Way, James Rudd, Chen Wang, et al.
The Journal of Clinical Investigation|May 15, 2026
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clustersGaelle Haddad, Junyu Guo, Yin Xi, et al.
Frontiers in Immunology|August 10, 2023
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MMSandy Wong, Habib Hamidi, Luciano J Costa, et al.
Genome Medicine|July 15, 2025
Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroupsEnze Liu, Oumaima Jaouadi, Riya Sharma, et al.
The Prostate|April 18, 2022
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimensKobe C Yuen, Ben Tran, Angelyn Anton, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2022
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple MyelomaFredrik Schjesvold, Bruno Paiva, Vincent Ribrag, et al.
Molecular Oncology|January 24, 2025
Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunctionConnor S Murphy, Heather Fairfield, Victoria E DeMambro, et al.
Leukemia & Lymphoma|January 20, 2022
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemiaPanayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, et al.
Molecular Cancer Therapeutics|March 16, 2013
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growthEdward B Garon, Richard S Finn, Habib Hamidi, et al.
Pageof 5